Photo of Tommy Tobin

Thomas Tobin’s practice focuses on complex commercial litigation and class action matters involving statutory, constitutional, and regulatory issues in a range of industries, including food and beverage, consumer packaged goods, and cannabis. In the food and beverage sector, Tommy has experience defending false advertising claims and consumer protection claims for well-known international corporations.

On January 12, 2024, a 252-page memorandum from the U.S. Department of Health & Human Services (“HHS”) was publicly released. This memorandum, dated August 29, 2023, portends a potential monumental shift in the regulation of marijuana under federal law and recommends that marijuana be regulated under schedule III of the Controlled Substances Act (“CSA”). The

Cannabis: In Focus

  • New York State Regulators Approve Final Adult-Use Regulations as Judge Bars New York State From Issuing New Cannabis Licenses
  • California Attorney General Partners With Cities To Address Illicit Cannabis Businesses
  • USDA Hemp Industry Updates

Continue Reading Cannabis Legal Report – Week of September 11, 2023

Cannabis: In Focus

  • VA Continues to Prohibit Doctors from Prescribing Cannabis to Veteran Patients
  • NY Judge Issues Court Order to Halt Cannabis Business Licensing
  • DEA Email Suggests DEA Considers Delta-8 THC a Controlled Substance
  • THC Testing Class Action Claims Proceed against Cannabis Company

Continue Reading Cannabis Legal Report – Week of August 14, 2023

Cannabis: In Focus

  • Congressional Activity—New Hearing and Bipartisan Bill on Hemp
  • Vermont Cannabis Cultivators Refused Federal Relief After Floods
  • DEA to Request Timeline for Administration’s Scheduling Review of Cannabis

Continue Reading Cannabis Legal Report—Week of August 7, 2023

On July 12, 2023, the U.S. Food and Drug Administration (FDA) released a public inventory of certain food ingredients that the agency has determined are unsafe because they are unapproved food additives that are not Generally Recognized as Safe (GRAS) when used as intended. FDA developed this inventory as part of its post-market surveillance of

Cannabis: In Focus

  • FDA and FTC Issue Cease and Desist Letters to Companies Selling Delta-8 Edibles
  • FDA Releases Draft Guidance for Psychedelic Drug Research
  • Federal Agencies Investigating Former Oregon Secretary of State’s Ties to Cannabis Company
  • “Plain” Packaging Guidelines for Missouri Cannabis Products Go Into Effect July 30

Continue Reading Cannabis Legal Report—Week of July 17, 2023

Cannabis: In Focus

  • DEA Announces New Guidance for Synthetic Cannabinoids
  • Oregon To Hold Landowners Responsible for Illegal Cannabis Grow Operations
  • States Provide State-Level Tax Relief to Cannabis Businesses
  • D.C. Superior Court Rules Cannabis Odor Constituted a Nuisance
  • New Suit Alleges Illicit Cannabis Operations Harm State-Legal Retailers

Continue Reading Cannabis Legal Report—Week of June 19, 2023